Expanded Access Policy

Codagenix Inc. (www.codagenix.com) is developing investigational vaccines for the prevention of a variety of infectious diseases. Our vaccines are in early stages of development; therefore, their potential risks and benefits are in the process of being evaluated. Participation in clinical trials should be the primary route by which patients obtain access to investigational vaccines and contribute to the collection of safety and efficacy data needed to support regulatory approval worldwide. Because our vaccines by their nature are designed for prophylaxis, not treatment use, Codagenix does not intend to offer Expanded Access to these investigational vaccines. To learn more about available clinical trials, please visit www.clinicaltrials.gov and search using the company name.